Nurix Therapeutics Starts Phase 1b/2 CLL Trial With Roche

Nurix has enrolled the first patient in a Phase 1b/2 study of bexobrutinib plus venetoclax in CLL/SLL, conducted under its collaboration with Roche. Data from this trial are intended to guide future registrational strategies and potential antibody combinations.